Falk RH, Comenzo RL, Skinner M. The systemic amyloidoses. N Engl J Med 1997;337:898–909.

• PubMed
Falk RH, Comenzo RL, Skinner M. The systemic amyloidoses. N Engl J Med 1997;337:898–909.9302305)| false
• Search Google Scholar
• Export Citation

Quock TP, Yan T, Chang E, et al. Epidemiology of AL amyloidosis: a real-world study using US claims data. Blood Adv 2018;2:1046–1053.

• PubMed
Quock TP, Yan T, Chang E, Epidemiology of AL amyloidosis: a real-world study using US claims data. Blood Adv 2018;2:1046–1053.29748430)| false
• Search Google Scholar
• Export Citation

Dispenzieri A, Kyle R, Merlini G, et al. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia 2009;23:215–224.

• PubMed
Dispenzieri A, Kyle R, Merlini G, International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia 2009;23:215–224.)| false
• Search Google Scholar
• Export Citation

van Gameren II, Hazenberg BP, Bijzet J, et al. Diagnostic accuracy of subcutaneous abdominal fat tissue aspiration for detecting systemic amyloidosis and its utility in clinical practice. Arthritis Rheum 2006;54:2015–2021.

• PubMed
van Gameren II, Hazenberg BP, Bijzet J, Diagnostic accuracy of subcutaneous abdominal fat tissue aspiration for detecting systemic amyloidosis and its utility in clinical practice. Arthritis Rheum 2006;54:2015–2021.16732553)| false
• Search Google Scholar
• Export Citation

van Gameren II, Hazenberg BP, Bijzet J, et al. Amyloid load in fat tissue reflects disease severity and predicts survival in amyloidosis. Arthritis Care Res (Hoboken) 2010;62:296–301.

• PubMed
van Gameren II, Hazenberg BP, Bijzet J, Amyloid load in fat tissue reflects disease severity and predicts survival in amyloidosis. Arthritis Care Res (Hoboken) 2010;62:296–301.20391474)| false
• Search Google Scholar
• Export Citation

Swan N, Skinner M, O’Hara CJ. Bone marrow core biopsy specimens in AL (primary) amyloidosis. A morphologic and immunohistochemical study of 100 cases. Am J Clin Pathol 2003;120:610–616.

• PubMed
Swan N, Skinner M, O’Hara CJ. Bone marrow core biopsy specimens in AL (primary) amyloidosis. A morphologic and immunohistochemical study of 100 cases. Am J Clin Pathol 2003;120:610–616.14560572)| false
• Search Google Scholar
• Export Citation

Lachmann HJ, Wechalekar AD, Gillmore JD. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med 2008;358:91–92; author reply 92–93.

• PubMed
Lachmann HJ, Wechalekar AD, Gillmore JD. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med 2008;358:91–92; author reply 92–93.18175386)| false
• Search Google Scholar
• Export Citation

Lavatelli F, Perlman DH, Spencer B, et al. Amyloidogenic and associated proteins in systemic amyloidosis proteome of adipose tissue. Mol Cell Proteomics 2008;7:1570–1583.

• PubMed
Lavatelli F, Perlman DH, Spencer B, Amyloidogenic and associated proteins in systemic amyloidosis proteome of adipose tissue. Mol Cell Proteomics 2008;7:1570–1583.18474516)| false
• Search Google Scholar
• Export Citation

Vrana JA, Gamez JD, Madden BJ, et al. Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens. Blood 2009;114:4957–4959.

• PubMed
Vrana JA, Gamez JD, Madden BJ, Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens. Blood 2009;114:4957–4959.19797517)| false
• Search Google Scholar
• Export Citation

Brambilla F, Lavatelli F, Di Silvestre D, et al. Reliable typing of systemic amyloidoses through proteomic analysis of subcutaneous adipose tissue. Blood 2012;119:1844–1847.

• PubMed
Brambilla F, Lavatelli F, Di Silvestre D, Reliable typing of systemic amyloidoses through proteomic analysis of subcutaneous adipose tissue. Blood 2012;119:1844–1847.21917755)| false
• Search Google Scholar
• Export Citation

Gilbertson JA, Theis JD, Vrana JA, et al. A comparison of immunohistochemistry and mass spectrometry for determining the amyloid fibril protein from formalin-fixed biopsy tissue. J Clin Pathol 2015;68:314–317.

• PubMed
Gilbertson JA, Theis JD, Vrana JA, A comparison of immunohistochemistry and mass spectrometry for determining the amyloid fibril protein from formalin-fixed biopsy tissue. J Clin Pathol 2015;68:314–317.25637636)| false
• Search Google Scholar
• Export Citation

Dispenzieri A, Gertz MA, Kyle RA, et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol 2004;22:3751–3757.

• PubMed
Dispenzieri A, Gertz MA, Kyle RA, Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol 2004;22:3751–3757.15365071)| false
• Search Google Scholar
• Export Citation

Palladini G, Campana C, Klersy C, et al. Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation 2003;107:2440–2445.

• PubMed
Palladini G, Campana C, Klersy C, Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation 2003;107:2440–2445.12719281)| false
• Search Google Scholar
• Export Citation

Choufani EB, Sanchorawala V, Ernst T, et al. Acquired factor X deficiency in patients with amyloid light-chain amyloidosis: incidence, bleeding manifestations, and response to high-dose chemotherapy. Blood 2001;97:1885–1887.

• PubMed
Choufani EB, Sanchorawala V, Ernst T, Acquired factor X deficiency in patients with amyloid light-chain amyloidosis: incidence, bleeding manifestations, and response to high-dose chemotherapy. Blood 2001;97:1885–1887.11238135)| false
• Search Google Scholar
• Export Citation

Thompson CA, Kyle R, Gertz M, et al. Systemic AL amyloidosis with acquired factor X deficiency: a study of perioperative bleeding risk and treatment outcomes in 60 patients. Am J Hematol 2010;85:171–173.

• PubMed
Thompson CA, Kyle R, Gertz M, Systemic AL amyloidosis with acquired factor X deficiency: a study of perioperative bleeding risk and treatment outcomes in 60 patients. Am J Hematol 2010;85:171–173.20052750)| false
• Search Google Scholar
• Export Citation

Comenzo RL, Zhou P, Fleisher M, et al. Seeking confidence in the diagnosis of systemic AL (Ig light-chain) amyloidosis: patients can have both monoclonal gammopathies and hereditary amyloid proteins. Blood 2006;107:3489–3491.

• PubMed
Comenzo RL, Zhou P, Fleisher M, Seeking confidence in the diagnosis of systemic AL (Ig light-chain) amyloidosis: patients can have both monoclonal gammopathies and hereditary amyloid proteins. Blood 2006;107:3489–3491.16439680)| false
• Search Google Scholar
• Export Citation

Lachmann HJ, Booth DR, Booth SE, et al. Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. N Engl J Med 2002;346:1786–1791.

• PubMed
Lachmann HJ, Booth DR, Booth SE, Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. N Engl J Med 2002;346:1786–1791.12050338)| false
• Search Google Scholar
• Export Citation

Maceira AM, Joshi J, Prasad SK, et al. Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation 2005;111:186–193.

• PubMed
Maceira AM, Joshi J, Prasad SK, Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation 2005;111:186–193.15630027)| false
• Search Google Scholar
• Export Citation

Kumar S, Dispenzieri A, Lacy MQ, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol 2012;30:989–995.

• PubMed
Kumar S, Dispenzieri A, Lacy MQ, Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol 2012;30:989–995.22331953)| false
• Search Google Scholar
• Export Citation

Muchtar E, Kumar SK, Gertz MA, et al. Staging systems use for risk stratification of systemic amyloidosis in the era of high-sensitivity troponin T assay. Blood 2019;133:763–766.

• PubMed
Muchtar E, Kumar SK, Gertz MA, Staging systems use for risk stratification of systemic amyloidosis in the era of high-sensitivity troponin T assay. Blood 2019;133:763–766.30545829)| false
• Search Google Scholar
• Export Citation

Gertz MA, Comenzo R, Falk RH, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18–22 April 2004. Am J Hematol 2005;79:319–328.

• PubMed
Gertz MA, Comenzo R, Falk RH, Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18–22 April 2004. Am J Hematol 2005;79:319–328.16044444)| false
• Search Google Scholar
• Export Citation

Gertz MA, Merlini G. Definition of organ involvement and response to treatment in AL amyloidosis: an updated consensus opinion. Amyloid 2010;17:48–49.

• PubMed
Gertz MA, Merlini G. Definition of organ involvement and response to treatment in AL amyloidosis: an updated consensus opinion. Amyloid 2010;17:48–49.)| false
• Search Google Scholar
• Export Citation

Palladini G, Dispenzieri A, Gertz MA, et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol 2012;30:4541–4549.

• PubMed
Palladini G, Dispenzieri A, Gertz MA, New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol 2012;30:4541–4549.23091105)| false
• Search Google Scholar
• Export Citation

Palladini G, Schönland SO, Sanchorawala V, et al. Clarification on the definition of complete haematologic response in light-chain (AL) amyloidosis. Amyloid 2021;28:1–2.

• PubMed
Palladini G, Schönland SO, Sanchorawala V, Clarification on the definition of complete haematologic response in light-chain (AL) amyloidosis. Amyloid 2021;28:1–2.33410355)| false
• Search Google Scholar
• Export Citation

Sidiqi MH, Aljama MA, Muchtar E, et al. Autologous stem cell transplant for immunoglobulin light chain amyloidosis patients aged 70 to 75. Biol Blood Marrow Transplant 2018;24:2157–2159.

• PubMed
Sidiqi MH, Aljama MA, Muchtar E, Autologous stem cell transplant for immunoglobulin light chain amyloidosis patients aged 70 to 75. Biol Blood Marrow Transplant 2018;24:2157–2159.29933071)| false
• Search Google Scholar
• Export Citation

Al Saleh AS, Sidiqi MH, Muchtar E, et al. Outcomes of patients with light chain amyloidosis who had autologous stem cell transplantation with 3 or more organs involved. Biol Blood Marrow Transplant 2019;25:1520–1525.

• PubMed
Al Saleh AS, Sidiqi MH, Muchtar E, Outcomes of patients with light chain amyloidosis who had autologous stem cell transplantation with 3 or more organs involved. Biol Blood Marrow Transplant 2019;25:1520–1525.)| false
• Search Google Scholar
• Export Citation

Palladini G, Kastritis E, Maurer MS, et al. Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA. Blood 2020;136:71–80.

• PubMed
Palladini G, Kastritis E, Maurer MS, Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA. Blood 2020;136:71–80.32244252)| false
• Search Google Scholar
• Export Citation

Kastritis E, Palladini G, Minnema MC, et al. Daratumumab-based treatment of immunoglobulin light-chain amyloidosis. N Engl J Med 2021;385:46–58.

• PubMed
Kastritis E, Palladini G, Minnema MC, Daratumumab-based treatment of immunoglobulin light-chain amyloidosis. N Engl J Med 2021;385:46–58.34192431)| false
• Search Google Scholar
• Export Citation

Mikhael JR, Schuster SR, Jimenez-Zepeda VH, et al. Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis. Blood 2012;119:4391–4394.

• PubMed
Mikhael JR, Schuster SR, Jimenez-Zepeda VH, Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis. Blood 2012;119:4391–4394.22331188)| false
• Search Google Scholar
• Export Citation

Venner CP, Lane T, Foard D, et al. Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival. Blood 2012;119:4387–4390.

• PubMed
Venner CP, Lane T, Foard D, Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival. Blood 2012;119:4387–4390.22331187)| false
• Search Google Scholar
• Export Citation

Shah GL, Kaul E, Fallo S, et al. Subcutaneous bortezomib in combination regimens in newly diagnosed patients with myeloma or systemic AL amyloidosis: high response rates and minimal toxicity. Blood 2012;120:Abstract 2968.

• PubMed
Shah GL, Kaul E, Fallo S, Subcutaneous bortezomib in combination regimens in newly diagnosed patients with myeloma or systemic AL amyloidosis: high response rates and minimal toxicity. Blood 2012;120:Abstract 2968.)| false
• Search Google Scholar
• Export Citation

Palladini G, Sachchithanantham S, Milani P, et al. A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis. Blood 2015;126:612–615.

• PubMed
Palladini G, Sachchithanantham S, Milani P, A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis. Blood 2015;126:612–615.25987656)| false
• Search Google Scholar
• Export Citation

Kastritis E, Wechalekar AD, Dimopoulos MA, et al. Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis. J Clin Oncol 2010;28:1031–1037.

• PubMed
Kastritis E, Wechalekar AD, Dimopoulos MA, Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis. J Clin Oncol 2010;28:1031–1037.)| false
• Search Google Scholar
• Export Citation

Wechalekar AD, Lachmann HJ, Offer M, et al. Efficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal disease. Haematologica 2008;93:295–298.

• PubMed
Wechalekar AD, Lachmann HJ, Offer M, Efficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal disease. Haematologica 2008;93:295–298.18245653)| false
• Search Google Scholar
• Export Citation

Lamm W, Willenbacher W, Lang A, et al. Efficacy of the combination of bortezomib and dexamethasone in systemic AL amyloidosis. Ann Hematol 2011;90:201–206.

• PubMed
Lamm W, Willenbacher W, Lang A, Efficacy of the combination of bortezomib and dexamethasone in systemic AL amyloidosis. Ann Hematol 2011;90:201–206.20821326)| false
• Search Google Scholar
• Export Citation

Singh V, Saad A, Palmer J, et al. Response to bortezomib based induction therapy in newly diagnosed light chain (AL) amyloidosis. Blood 2009;114:Abstract 1867.

• PubMed
Singh V, Saad A, Palmer J, Response to bortezomib based induction therapy in newly diagnosed light chain (AL) amyloidosis. Blood 2009;114:Abstract 1867.)| false
• Search Google Scholar
• Export Citation

Reece DE, Hegenbart U, Sanchorawala V, et al. Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study. Blood 2011;118:865–873.

• PubMed
Reece DE, Hegenbart U, Sanchorawala V, Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study. Blood 2011;118:865–873.21562045)| false
• Search Google Scholar
• Export Citation

Reece DE, Hegenbart U, Sanchorawala V, et al. Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis. Blood 2014;124:2498–2506.

• PubMed
Reece DE, Hegenbart U, Sanchorawala V, Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis. Blood 2014;124:2498–2506.25202139)| false
• Search Google Scholar
• Export Citation

Landau H, Hassoun H, Rosenzweig MA, et al. Bortezomib and dexamethasone consolidation following risk-adapted melphalan and stem cell transplantation for patients with newly diagnosed light-chain amyloidosis. Leukemia 2013;27:823–828.

• PubMed
Landau H, Hassoun H, Rosenzweig MA, Bortezomib and dexamethasone consolidation following risk-adapted melphalan and stem cell transplantation for patients with newly diagnosed light-chain amyloidosis. Leukemia 2013;27:823–828.23014566)| false
• Search Google Scholar
• Export Citation

Gasparetto C, Sanchorawala V, Snyder RM, et al. Use of melphalan (M)/dexamethasone (D)/bortezomib in AL amyloidosis. J Clin Oncol 2010;28:Abstract 8024.

• PubMed
Gasparetto C, Sanchorawala V, Snyder RM, Use of melphalan (M)/dexamethasone (D)/bortezomib in AL amyloidosis. J Clin Oncol 2010;28:Abstract 8024.)| false
• Search Google Scholar
• Export Citation

Zonder J, Sanchorawala V, Snyder R. Rapid haematologic and organ responses in patients with AL amyloid treated with bortezomib plus melphalan and dexamethasone. Amyloid 2010;17:86.

• PubMed
Zonder J, Sanchorawala V, Snyder R. Rapid haematologic and organ responses in patients with AL amyloid treated with bortezomib plus melphalan and dexamethasone. Amyloid 2010;17:86.)| false
• Search Google Scholar
• Export Citation

Kastritis E, Leleu X, Arnulf B, et al. Bortezomib, melphalan, and dexamethasone for light-chain amyloidosis. J Clin Oncol 2020;38:3252–3260.

• PubMed
Kastritis E, Leleu X, Arnulf B, Bortezomib, melphalan, and dexamethasone for light-chain amyloidosis. J Clin Oncol 2020;38:3252–3260.32730181)| false
• Search Google Scholar
• Export Citation

Kastritis E, Dialoupi I, Gavriatopoulou M, et al. Primary treatment of light-chain amyloidosis with bortezomib, lenalidomide, and dexamethasone. Blood Adv 2019;3:3002–3009.

• PubMed
Kastritis E, Dialoupi I, Gavriatopoulou M, Primary treatment of light-chain amyloidosis with bortezomib, lenalidomide, and dexamethasone. Blood Adv 2019;3:3002–3009.31648323)| false
• Search Google Scholar
• Export Citation

Palladini G, Milani P, Foli A, et al. Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach. Haematologica 2014;99:743–750.

• PubMed
Palladini G, Milani P, Foli A, Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach. Haematologica 2014;99:743–750.24213149)| false
• Search Google Scholar
• Export Citation

Kastritis E, Anagnostopoulos A, Roussou M, et al. Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone. Haematologica 2007;92:1351–1358.

• PubMed
Kastritis E, Anagnostopoulos A, Roussou M, Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone. Haematologica 2007;92:1351–1358.18024372)| false
• Search Google Scholar
• Export Citation

Reece DE, Sanchorawala V, Hegenbart U, et al. Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study. Blood 2009;114:1489–1497.

• PubMed
Reece DE, Sanchorawala V, Hegenbart U, Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study. Blood 2009;114:1489–1497.19498019)| false
• Search Google Scholar
• Export Citation

Kaufman GP, Schrier SL, Lafayette RA, et al. Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis. Blood 2017;130:900–902.

• PubMed
Kaufman GP, Schrier SL, Lafayette RA, Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis. Blood 2017;130:900–902.28615223)| false
• Search Google Scholar
• Export Citation

Schwotzer R, Manz MG, Pederiva S, et al. Daratumumab for relapsed or refractory AL amyloidosis with high plasma cell burden. Hematol Oncol 2019;37:595–600.

• PubMed
Schwotzer R, Manz MG, Pederiva S, Daratumumab for relapsed or refractory AL amyloidosis with high plasma cell burden. Hematol Oncol 2019;37:595–600.)| false
• Search Google Scholar
• Export Citation

Roussel M, Merlini G, Chevret S, et al. A prospective phase 2 trial of daratumumab in patients with previously treated systemic light-chain amyloidosis. Blood 2020;135:1531–1540.

• PubMed
Roussel M, Merlini G, Chevret S, A prospective phase 2 trial of daratumumab in patients with previously treated systemic light-chain amyloidosis. Blood 2020;135:1531–1540.32108228)| false
• Search Google Scholar
• Export Citation

Van de Wyngaert Z, Carpentier B, Pascal L, et al. Daratumumab is effective in the relapsed or refractory systemic light-chain amyloidosis but associated with high infection burden in a frail real-life population. Br J Haematol 2020;188:e24–27.

• PubMed
Van de Wyngaert Z, Carpentier B, Pascal L, Daratumumab is effective in the relapsed or refractory systemic light-chain amyloidosis but associated with high infection burden in a frail real-life population. Br J Haematol 2020;188:e24–27.31742668)| false
• Search Google Scholar
• Export Citation

Dispenzieri A, Kastritis E, Wechalekar AD, et al. Primary results from the phase 3 Tourmaline-AL1 trial of ixazomib-dexamethasone versus physician’s choice of therapy in patients (Pts) with relapsed/refractory primary systemic AL amyloidosis (RRAL). Blood 2019;134(Suppl_1):139.

• PubMed
Dispenzieri A, Kastritis E, Wechalekar AD, Primary results from the phase 3 Tourmaline-AL1 trial of ixazomib-dexamethasone versus physician’s choice of therapy in patients (Pts) with relapsed/refractory primary systemic AL amyloidosis (RRAL). Blood 2019;134(Suppl_1):139.)| false
• Search Google Scholar
• Export Citation

Cohen OC, Sharpley F, Gillmore JD, et al. Use of ixazomib, lenalidomide and dexamethasone in patients with relapsed amyloid light-chain amyloidosis. Br J Haematol 2020;189:643–649.

• PubMed
Cohen OC, Sharpley F, Gillmore JD, Use of ixazomib, lenalidomide and dexamethasone in patients with relapsed amyloid light-chain amyloidosis. Br J Haematol 2020;189:643–649.31984481)| false
• Search Google Scholar
• Export Citation

Kastritis E, Terpos E, Roussou M, et al. A phase 1/2 study of lenalidomide with low-dose oral cyclophosphamide and low-dose dexamethasone (RdC) in AL amyloidosis. Blood 2012;119:5384–5390.

• PubMed
Kastritis E, Terpos E, Roussou M, A phase 1/2 study of lenalidomide with low-dose oral cyclophosphamide and low-dose dexamethasone (RdC) in AL amyloidosis. Blood 2012;119:5384–5390.22517904)| false
• Search Google Scholar
• Export Citation

Kumar SK, Hayman SR, Buadi FK, et al. Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial. Blood 2012;119:4860–4867.

• PubMed
Kumar SK, Hayman SR, Buadi FK, Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial. Blood 2012;119:4860–4867.22504925)| false
• Search Google Scholar
• Export Citation

Palladini G, Russo P, Milani P, et al. A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis. Haematologica 2013;98:433–436.

• PubMed
Palladini G, Russo P, Milani P, A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis. Haematologica 2013;98:433–436.22983583)| false
• Search Google Scholar
• Export Citation

Dispenzieri A, Lacy MQ, Zeldenrust SR, et al. The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. Blood 2007;109:465–470.

• PubMed
Dispenzieri A, Lacy MQ, Zeldenrust SR, The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. Blood 2007;109:465–470.)| false
• Search Google Scholar
• Export Citation

Sanchorawala V, Wright DG, Rosenzweig M, et al. Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial. Blood 2007;109:492–496.

• PubMed
Sanchorawala V, Wright DG, Rosenzweig M, Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial. Blood 2007;109:492–496.16960148)| false
• Search Google Scholar
• Export Citation

Mahmood S, Venner CP, Sachchithanantham S, et al. Lenalidomide and dexamethasone for systemic AL amyloidosis following prior treatment with thalidomide or bortezomib regimens. Br J Haematol 2014;166:842–848.

• PubMed
Mahmood S, Venner CP, Sachchithanantham S, Lenalidomide and dexamethasone for systemic AL amyloidosis following prior treatment with thalidomide or bortezomib regimens. Br J Haematol 2014;166:842–848.)| false
• Search Google Scholar
• Export Citation

Comenzo RL, Gertz MA. Autologous stem cell transplantation for primary systemic amyloidosis. Blood 2002;99:4276–4282.

• PubMed
Comenzo RL, Gertz MA. Autologous stem cell transplantation for primary systemic amyloidosis. Blood 2002;99:4276–4282.12036853)| false
• Search Google Scholar
• Export Citation

Gertz MA, Lacy MQ, Dispenzieri A, et al. Stem cell transplantation for the management of primary systemic amyloidosis. Am J Med 2002;113:549–555.

• PubMed
Gertz MA, Lacy MQ, Dispenzieri A, Stem cell transplantation for the management of primary systemic amyloidosis. Am J Med 2002;113:549–555.12459400)| false
• Search Google Scholar
• Export Citation

Goodman HJ, Gillmore JD, Lachmann HJ, et al. Outcome of autologous stem cell transplantation for AL amyloidosis in the UK. Br J Haematol 2006;134:417–425.

• PubMed
Goodman HJ, Gillmore JD, Lachmann HJ, Outcome of autologous stem cell transplantation for AL amyloidosis in the UK. Br J Haematol 2006;134:417–425.16822290)| false
• Search Google Scholar
• Export Citation

Jimenez-Zepeda VH, Franke N, Delgado D, et al. High-dose melphalan for AL amyloidosis: the importance of case selection to improve clinical outcomes. Blood 2010;116:Abstract 2403.

• PubMed
Jimenez-Zepeda VH, Franke N, Delgado D, High-dose melphalan for AL amyloidosis: the importance of case selection to improve clinical outcomes. Blood 2010;116:Abstract 2403.)| false
• Search Google Scholar
• Export Citation

Wechalekar AD, Schonland SO, Kastritis E, et al. A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. Blood 2013;121:3420–3427.

• PubMed
Wechalekar AD, Schonland SO, Kastritis E, A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. Blood 2013;121:3420–3427.23479568)| false
• Search Google Scholar
• Export Citation

Sanchorawala V. Role of high-dose melphalan and autologous peripheral blood stem cell transplantation in AL amyloidosis. Am J Blood Res 2012;2:9–17.

• PubMed
Sanchorawala V. Role of high-dose melphalan and autologous peripheral blood stem cell transplantation in AL amyloidosis. Am J Blood Res 2012;2:9–17.22432083)| false
• Search Google Scholar
• Export Citation

Cordes S, Dispenzieri A, Lacy MQ, et al. Ten-year survival after autologous stem cell transplantation for immunoglobulin light chain amyloidosis. Cancer 2012;118:6105–6109.

• PubMed
Cordes S, Dispenzieri A, Lacy MQ, Ten-year survival after autologous stem cell transplantation for immunoglobulin light chain amyloidosis. Cancer 2012;118:6105–6109.22707405)| false
• Search Google Scholar
• Export Citation

Dispenzieri A, Kyle RA, Lacy MQ, et al. Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study. Blood 2004;103:3960–3963.

• PubMed
Dispenzieri A, Kyle RA, Lacy MQ, Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study. Blood 2004;103:3960–3963.14739213)| false
• Search Google Scholar
• Export Citation

Gertz MA, Lacy MQ, Dispenzieri A, et al. Effect of hematologic response on outcome of patients undergoing transplantation for primary amyloidosis: importance of achieving a complete response. Haematologica 2007;92:1415–1418.

• PubMed
Gertz MA, Lacy MQ, Dispenzieri A, Effect of hematologic response on outcome of patients undergoing transplantation for primary amyloidosis: importance of achieving a complete response. Haematologica 2007;92:1415–1418.17768110)| false
• Search Google Scholar
• Export Citation

Skinner M, Sanchorawala V, Seldin DC, et al. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med 2004;140:85–93.

• PubMed
Skinner M, Sanchorawala V, Seldin DC, High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med 2004;140:85–93.14734330)| false
• Search Google Scholar
• Export Citation

Kumar SK, Dispenzieri A, Lacy MQ, et al. Changes in serum-free light chain rather than intact monoclonal immunoglobulin levels predicts outcome following therapy in primary amyloidosis. Am J Hematol 2011;86:251–255.

• PubMed
Kumar SK, Dispenzieri A, Lacy MQ, Changes in serum-free light chain rather than intact monoclonal immunoglobulin levels predicts outcome following therapy in primary amyloidosis. Am J Hematol 2011;86:251–255.21328431)| false
• Search Google Scholar
• Export Citation

Gertz MA, Lacy MQ, Dispenzieri A, et al. Risk-adjusted manipulation of melphalan dose before stem cell transplantation in patients with amyloidosis is associated with a lower response rate. Bone Marrow Transplant 2004;34:1025–1031.

• PubMed
Gertz MA, Lacy MQ, Dispenzieri A, Risk-adjusted manipulation of melphalan dose before stem cell transplantation in patients with amyloidosis is associated with a lower response rate. Bone Marrow Transplant 2004;34:1025–1031.15516945)| false
• Search Google Scholar
• Export Citation

Perfetti V, Siena S, Palladini G, et al. Long-term results of a risk-adapted approach to melphalan conditioning in autologous peripheral blood stem cell transplantation for primary (AL) amyloidosis. Haematologica 2006;91:1635–1643.

• PubMed
Perfetti V, Siena S, Palladini G, Long-term results of a risk-adapted approach to melphalan conditioning in autologous peripheral blood stem cell transplantation for primary (AL) amyloidosis. Haematologica 2006;91:1635–1643.17145600)| false
• Search Google Scholar
• Export Citation

Cibeira MT, Sanchorawala V, Seldin DC, et al. Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients. Blood 2011;118:4346–4352.

• PubMed
Cibeira MT, Sanchorawala V, Seldin DC, Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients. Blood 2011;118:4346–4352.)| false
• Search Google Scholar
• Export Citation

Gertz MA, Lacy MQ, Dispenzieri A, et al. Trends in day 100 and 2-year survival after auto-SCT for AL amyloidosis: outcomes before and after 2006. Bone Marrow Transplant 2011;46:970–975.

• PubMed
Gertz MA, Lacy MQ, Dispenzieri A, Trends in day 100 and 2-year survival after auto-SCT for AL amyloidosis: outcomes before and after 2006. Bone Marrow Transplant 2011;46:970–975.20935685)| false
• Search Google Scholar
• Export Citation

Sanchorawala V, Sun F, Quillen K, et al. Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem cell transplantation: 20-year experience. Blood 2015;126:2345–2347.

• PubMed
Sanchorawala V, Sun F, Quillen K, Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem cell transplantation: 20-year experience. Blood 2015;126:2345–2347.26443620)| false
• Search Google Scholar
• Export Citation

Tsai SB, Seldin DC, Quillen K, et al. High-dose melphalan and stem cell transplantation for patients with AL amyloidosis: trends in treatment-related mortality over the past 17 years at a single referral center. Blood 2012;120:4445–4446.

• PubMed
Tsai SB, Seldin DC, Quillen K, High-dose melphalan and stem cell transplantation for patients with AL amyloidosis: trends in treatment-related mortality over the past 17 years at a single referral center. Blood 2012;120:4445–4446.)| false
• Search Google Scholar
• Export Citation

Palladini G, Perfetti V, Obici L, et al. Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood 2004;103:2936–2938.

• PubMed
Palladini G, Perfetti V, Obici L, Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood 2004;103:2936–2938.15070667)| false
• Search Google Scholar
• Export Citation

Palladini G, Russo P, Nuvolone M, et al. Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis. Blood 2007;110:787–788.

• PubMed
Palladini G, Russo P, Nuvolone M, Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis. Blood 2007;110:787–788.17606766)| false
• Search Google Scholar
• Export Citation

Jaccard A, Moreau P, Leblond V, et al. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med 2007;357:1083–1093.

• PubMed
Jaccard A, Moreau P, Leblond V, High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med 2007;357:1083–1093.17855669)| false
• Search Google Scholar
• Export Citation

Jaccard A, Leblond V, Royer B, et al. Autologous stem cell transplantation (ASCT) versus oral melphalan and high-dose dexamethasone in patients with AL (primary) amyloidosis: long term follow-up of the French multicentric randomized trial. Blood 2010;116:Abstract 1344.

• PubMed
Jaccard A, Leblond V, Royer B, Autologous stem cell transplantation (ASCT) versus oral melphalan and high-dose dexamethasone in patients with AL (primary) amyloidosis: long term follow-up of the French multicentric randomized trial. Blood 2010;116:Abstract 1344.)| false
• Search Google Scholar
• Export Citation

Dispenzieri A, Buadi F, Laumann K, et al. Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis. Blood 2012;119:5397–5404.

• PubMed
Dispenzieri A, Buadi F, Laumann K, Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis. Blood 2012;119:5397–5404.22493299)| false
• Search Google Scholar
• Export Citation

Lentzsch S, Lagos GG, Comenzo RL, et al. Bendamustine with dexamethasone in relapsed/refractory systemic light-chain amyloidosis: results of a phase II study. J Clin Oncol 2020;38:1455–1462.

• PubMed
Lentzsch S, Lagos GG, Comenzo RL, Bendamustine with dexamethasone in relapsed/refractory systemic light-chain amyloidosis: results of a phase II study. J Clin Oncol 2020;38:1455–1462.32083996)| false
• Search Google Scholar
• Export Citation

Cohen AD, Landau H, Scott EC, et al. Safety and efficacy of carfilzomib (CFZ) in previously-treated systemic light-chain (AL) amyloidosis. Blood 2016;128:645.

• PubMed
Cohen AD, Landau H, Scott EC, Safety and efficacy of carfilzomib (CFZ) in previously-treated systemic light-chain (AL) amyloidosis. Blood 2016;128:645.)| false
• Search Google Scholar
• Export Citation

Premkumar VJ, Lentzsch S, Pan S, et al. Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis. Blood Cancer J 2021;11:10.

• PubMed
Premkumar VJ, Lentzsch S, Pan S, Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis. Blood Cancer J 2021;11:10.)| false
• Search Google Scholar
• Export Citation

Wechalekar AD, Whelan C. Encouraging impact of doxycycline on early mortality in cardiac light chain (AL) amyloidosis. Blood Cancer J 2017;7:e546.

• PubMed
Wechalekar AD, Whelan C. Encouraging impact of doxycycline on early mortality in cardiac light chain (AL) amyloidosis. Blood Cancer J 2017;7:e546.28338670)| false
• Search Google Scholar
• Export Citation

D’Souza A, Flynn K, Chhabra S, et al. Rationale and design of DUAL study: doxycycline to upgrade response in light chain (AL) amyloidosis (DUAL): a phase 2 pilot study of a two-pronged approach of prolonged doxycycline with plasma cell-directed therapy in the treatment of AL amyloidosis. Contemp Clin Trials Commun 2017;8:33–38.

• PubMed
D’Souza A, Flynn K, Chhabra S, Rationale and design of DUAL study: doxycycline to upgrade response in light chain (AL) amyloidosis (DUAL): a phase 2 pilot study of a two-pronged approach of prolonged doxycycline with plasma cell-directed therapy in the treatment of AL amyloidosis. Contemp Clin Trials Commun 2017;8:33–38.29696194)| false
• Search Google Scholar
• Export Citation

Shen KN, Fu WJ, Wu Y, et al. Doxycycline combined with bortezomib- cyclophosphamide-dexamethasone chemotherapy for newly diagnosed cardiac light-chain amyloidosis: a multicenter randomized controlled trial. Circulation 2022;145:8–17.

• PubMed
Shen KN, Fu WJ, Wu Y, Doxycycline combined with bortezomib- cyclophosphamide-dexamethasone chemotherapy for newly diagnosed cardiac light-chain amyloidosis: a multicenter randomized controlled trial. Circulation 2022;145:8–17.34503349)| false
• Search Google Scholar
• Export Citation

Wechalekar AD, Cibeira MT, Gibbs SD, et al. Guidelines for non- transplant chemotherapy for treatment of systemic AL amyloidosis: EHA-ISA working group. Amyloid. Published online July 15, 2022. doi:10.1080/13506129.2022.2093635

• PubMed
Wechalekar AD, Cibeira MT, Gibbs SD, Guidelines for non- transplant chemotherapy for treatment of systemic AL amyloidosis: EHA-ISA working group. Amyloid. Published online July 15, 2022. doi:10.1080/13506129.2022.2093635)| false
• Search Google Scholar
• Export Citation